A new paper form the Neurobiology Lab in npj Parkinson’s Disease reports early, disease-relevant changes that may help explain the selective susceptibility of midbrain dopaminergic neurons in Parkinson’s disease. Using human iPSC-derived midbrain organoids carrying SNCA triplication (a genetic cause of synucleinopathy), the authors mapped molecular and structural alterations before overt dopaminergic neuron loss.
Statoulla, Zafeiri et al. show that increased SNCA dosage triggers early disruption of proteostasis-related signalling, including pathways linked to protein synthesis control and cellular stress responses, prior to pronounced neurodegeneration. Multi-omics analyses further revealed coordinated shifts in neuronal programs and stress-linked pathways, consistent with a system under increasing proteostatic pressure.
Importantly, the work also highlights early remodeling of the extracellular environment: proteomic/transcriptomic signatures pointed to altered extracellular matrix (ECM) composition, with enrichment of perineuronal net (PNN)-associated components, and imaging showed increased pericellular/interstitial matrix structures that emerged earlier around TH+ dopaminergic neurons. Ribosome profiling suggested selective translational buffering affecting subsets of neuronal and matrix-related transcripts, indicating that translational regulation may shape these early phenotypes.
Together, these findings support a model in which dopaminergic neuron vulnerability is primed by an early convergence of proteostasis stress and ECM/PNN architecture changes, opening new angles for targeting the earliest stages of synucleinopathy.
Parkinson’s disease (PD) is the second most common neurodegenerative disorder and a rapidly growing cause of disability worldwide. It is defined clinically by progressive motor symptoms, but for many patients the burden extends well beyond movement, with prominent non-motor features including sleep disturbance, mood and cognitive changes, autonomic dysfunction, and fatigue. At the biological level, PD is driven by the gradual dysfunction and loss of midbrain dopaminergic neurons, leading to long-term impairment in basal ganglia circuits that control movement and behaviour. Current therapies can alleviate symptoms, yet they do not stop the underlying neurodegenerative process. This is why identifying the earliest, cell-type–specific mechanisms that make dopaminergic neurons uniquely vulnerable remains a central challenge, with direct implications for developing disease-modifying interventions and improving patient outcomes.
The work was supported by Erevno-Dimiourgo-Kainotomo PANTHER (Τ2ΕΔΚ-00852) and the Flagship action Brain Precision (TAEDR-0535850)
